Unmet Needs and Future Directions in Multiple Myeloma Treatment
The panel closes their discussions by highlighting current unmet needs in multiple myeloma treatment and what excites them on the horizon.
EP: 1.Induction Regimen Options for Patients with Transplant-Eligible NDMM
EP: 2.Selecting a Treatment Regimen for Patients with Transplant-Eligible NDMM
EP: 3.Measuring Treatment Response in Transplant-Eligible NDMM
EP: 4.First-Line Treatment Options in Transplant-Ineligible NDMM
EP: 5.Treatment Regimens for Frail Patients with Transplant-Ineligible NDMM
EP: 6.Goals and Duration of Treatment for Elderly Patients with Transplant-Ineligible NDMM
EP: 7.Currently Available Treatment Options for Relapsed/Refractory Multiple Myeloma
EP: 8.Novel Bispecific Agents in the Treatment of Multiple Myeloma
EP: 9.CAR T-Cell Therapy in Multiple Myeloma Treatment
Now Viewing
EP: 10.Unmet Needs and Future Directions in Multiple Myeloma Treatment
EP: 11.Recap: A Review of the Treatment Landscape in Multiple Myeloma
Recent Videos
![“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F267879fc15a40ec8d3ed04d8ee9c1f044b49ee89-2990x1692.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.")
Related Content
